Interstitial Signaling In Skeletal Muscle And Adipose Depots

Overview

About this study

The purpose of this study is to define depot-specific interstitial inflammatory and metabolic signaling in young and older adults.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Healthy men and women between the ages of 21-35 years or 65-85 years

Exclusion Criteria:

  • Diabetes or fasting plasma glucose ³126 mg/dL

  • Body mass index (BMI) ≤20 or ³30 kg/m2

  • Anemia (female subjects hemoglobin of ≤11 g/dl and male subjects hemoglobin ≤12 g/dl)

  • Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment)

  • Renal failure (serum creatinine >1.5mg/dl)

  • Chronic active liver disease (AST >144IU/L or ALT >165IU/L)

  • Oral warfarin group medications or history of blood clotting disorders.

  • Smoking

  • Pregnancy or breastfeeding

  • Alcohol consumption greater than 2 glasses/day

  • Untreated thyroid dysfunction (TSH undetectable or >6)

  • Thrombocytopenia (platelets <126)

  • Orthopedic  conditions or undiagnosed illness that could be exacerbated by study procedures

  • Use of medications known to influence study outcomes or increase risk, such as anticoagulants and chronic anti-inflammatory medications (NSAIDS, corticosteroids)

  • Debilitating chronic disease (at the discretion of the investigators)

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/23/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hawley Kunz, Ph.D.

Contact us for the latest status

Contact information:

Hawley Kunz

5072552061

kunz.hawley@mayo.edu

More information

Publications

Publications are currently not available